Form 4: Inmune Bio CEO Raymond Tesi Acquires 226,000 Stock Options

Inmune Bio's CEO, Raymond Tesi, was granted 226,000 stock options under the company's 2021 Stock Incentive Plan.

Summary

• Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc., has been granted 226,000 stock options.
• The options were granted on December 5, 2024, with an exercise price of $5.05 per share.
• These options will become fully vested and exercisable on December 5, 2026, two years after the grant date.
• The options expire on December 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting period encourages long-term commitment from the CEO.

Future Outlook

The stock options will vest in two years, incentivizing the CEO to increase shareholder value over that period.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting period of two years is typical for such grants.
• The exercise price of $5.05 is specific to Inmune Bio's stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, insider trading, executive compensation, Inmune Bio, Raymond Tesi, equity